VJHemOnc is committed to improving our service to you

ASH 2019 | CD19 CAR-T for CNS lymphoma

VJHemOnc is committed to improving our service to you

Tanya Siddiqi

Tanya Siddiqi, MD, City of Hope, Duarte, CA, discusses an ongoing phase I trial (NCT02153580) investigating an autologous CD19-specific, hinge-optimized, CD28 costimulatory CAR-T product for the treatment of relapsed/refractory B-cell non-Hodgkin lymphomas (NHL), including CNS lymphoma. Thus far, early results appear promising in patients with primary and secondary CNS lymphoma – a group with great unmet clinical need. Expansion phase enrollment is continuing and the group also plan to explore an intraventricular route of CAR-T delivery. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter